Answers are grounded in this paper and cite their sources.
Impaired diabetic wound healing is characterized by chronic inflammation, severe bioenergetic deficits, and excessive extracellular matrix (ECM) degradation driven by matrix metalloproteinases (MMPs). Here, a cell-free therapeutic strategy is developed utilizing exogenous calcium silicate-primed mitochondria (CSMito) embedded within a collagen hydrogel to overcome these pathological barriers. Multi-omics analyses reveal that silicate conditioning activates intracellular signaling cascades, shifting mitochondrial dynamics toward fusion and enriching CSMito with critical therapeutic cargos: UQCRC1 (respiratory Complex III) and tissue inhibitor of metalloproteinases 1 (TIMP-1). Upon transplantation, CSMito orchestrates a distinct dual-action mechanism. Extracellularly, surface-associated TIMP-1, confirmed via nano-flow cytometry, acts as a molecular shield to sequester host-secreted MMPs prior to cellular internalization, thereby preventing scaffold degradation. Intracellularly, following endocytosis, the UQCRC1-fortified respiratory chain rapidly restores oxidative phosphorylation capacity in recipient cells. This bioenergetic rescue mitigates oxidative stress and metabolically reprograms inflammatory macrophages toward a pro-resolving phenotype. Targeted loss-of-function studies using TIMP-1 depletion and Complex III pharmacological blockade confirm that both proteolytic shielding and metabolic reprogramming are essential for tissue resolution. In a diabetic rabbit full-thickness wound model, CSMito accelerates macroscopic closure, orchestrates dense collagen deposition, and stimulates robust angiogenesis. Ultimately, this work establishes inorganic ion-engineered mitochondria as advanced, dual-functional therapeutics to reverse diabetic wound chronicity.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: